Gamma Knife Market: Market Size & Forecast 2026

Gamma Knife radiosurgery delivers precisely focused beams of radiation to intracranial targets with sub-millimeter accuracy, making it a cornerstone technology in neurosurgical and radiation oncology departments. The global market in 2025 stands at approximately USD 495 million, with projected values across research firms ranging from about USD 468 million to USD 662 million, reflecting differences in estimation methodology and scope. Demand is underpinned by the device's established clinical efficacy for treating benign and malignant brain tumors, functional disorders such as trigeminal neuralgia, and vascular abnormalities. Because no official government statistical agency publishes dedicated market data for this medical device category, all available figures derive from proprietary industry research models and tracking of unit sales, installed base, and replacement cycles.

• •Treats brain tumors, AVMs, and functional neurological disorders via non-invasive stereotactic radiosurgery
• •2025 market value estimated between USD 468 million and USD 662 million across research firms; USD 495 million used as the central reference point
• •No government or official statistical agency publishes dedicated market size data for this medical device category

The primary driver of market expansion is the rising global incidence of brain tumors and neurological disorders, coupled with demographic aging that increases the patient pool requiring neurosurgical interventions. Growing preference for minimally invasive or non-invasive procedures over traditional open surgery, combined with expanding clinical evidence supporting radiosurgery outcomes, has broadened adoption across both developed and emerging healthcare systems. Reimbursement support from major healthcare payers and the continuous introduction of upgraded Gamma Knife models with enhanced planning software and automated patient positioning also sustain equipment replacement and upgrade cycles.

• •Rising incidence of brain tumors and neurological disorders worldwide, amplified by aging populations
• •Strong clinical track record and established reimbursement pathways support sustained institutional adoption
• •Technological upgrades to existing platforms and expanded clinical indications drive replacement and new-unit sales

The market is commonly segmented by product type, with Leksell Gamma Knife Perfexion and Icon platforms representing the dominant installed base, followed by competing stereotactic radiosurgery systems. End-user segmentation includes hospitals, specialty oncology centers, and academic medical institutions, with the hospital segment accounting for the majority of installations due to high capital cost and infrastructure requirements. Geographically, North America leads the market supported by advanced healthcare infrastructure, high procedural volumes, and favorable reimbursement environments, while Europe follows with strong adoption in Germany, the United Kingdom, and Scandinavian countries. Asia-Pacific is emerging as the fastest-growing regional segment, driven by rising healthcare investment in China, India, and Southeast Asian markets and increasing medical tourism for neurosurgical procedures.

• •North America leads in installed base and annual procedural volume, supported by established reimbursement frameworks
• •Europe holds the second-largest share, with Germany and the UK as key national markets
• •Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and medical tourism in China, India, and Southeast Asia

What are the recent trends and outlook?

Industry outlook through 2032 and beyond suggests continued mid-single-digit annual growth, with forecast CAGR estimates clustering around 5.0 percent to 5.7 percent depending on the research firm and time horizon. Key trends shaping the market include integration of artificial intelligence and machine learning into treatment planning software, robotics-enhanced patient positioning systems, and the development of MR-linac hybrid platforms that may complement rather than replace Gamma Knife workflows. Manufacturers are increasingly focused on upgrading existing installed units with software enhancements to extend product lifecycles and reduce the full capital cost barrier for hospitals considering initial acquisition. Looking forward, the market's growth trajectory will be influenced by the pace of healthcare infrastructure investment in emerging economies, ongoing clinical research expanding treatable indications, and the competitive dynamics between Gamma Knife radiosurgery and emerging alternative radiosurgical technologies.

• •Projected CAGR of approximately 5.0% to 5.7% through 2032-2034, with market size reaching roughly USD 691 million to USD 784 million
• •AI-driven treatment planning, robotic positioning, and software-centric upgrades are dominant product development themes
• •Future growth hinges on emerging-market hospital investment, expanded clinical indications, and competitive positioning against alternative radiosurgical platforms